Sichuan Qingmu Pharmaceutical Co., Ltd

Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Stock code: 688513).

Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs. 

Hit API products such as Dabigatran, have been commercialized in regulated markets and China. Qingmu is experienced on exporting API products to more than 40 countries and regions such as Japan, USA, Germany, Spain, the Netherlands, Russia, South Korea, Brazil, etc.

Focus on business in regulated markets, Qingmu was inspected and approved by US FDA, Korea MFDS, and China NMPA, and also approved by customer audit from China, Europe, USA and Japan, etc.